human
immunoglobulin
g
igg
use
treat
peopl
inherit
immunoglobulin
defici
sinc
bruton
infus
child
undetect
gamma
globulin
level
suffer
recurr
pneumococc
infect
subcutan
infus
gmo
produc
measur
gamma
globulin
level
complet
elimin
pneumococc
infect
human
igg
soon
becam
standard
treatment
patient
primari
antibodi
defici
develop
chronic
bacteri
infect
first
human
igg
produc
larg
scale
known
immun
serum
globulin
isg
produc
cold
ethanol
precipit
process
develop
earli
e
j
cohn
cowork
depart
physic
chemistri
harvard
medic
school
isg
formul
protein
concentr
mgml
contain
molar
glycin
weightvolum
sodium
chlorid
gl
merthiol
isg
solut
adjust
ph
ae
store
c
time
isg
solut
tend
form
particl
aggreg
storag
aggreg
gener
believ
caus
advers
event
isg
inject
intraven
therefor
first
commerci
immunoglobulin
restrict
intramuscular
subcutan
inject
spontan
complement
activ
anticompl
activ
igg
aggreg
propos
princip
caus
advers
side
reaction
isg
inject
intraven
desir
elimin
anticompl
activ
signific
impact
intraven
immunoglobulin
ivig
develop
manufactur
reduc
anticompl
activ
enzymat
digest
chemic
modif
first
ivig
produc
pepsin
digest
contain
princip
fragment
two
antigen
bind
site
link
disulfid
bond
desir
reduc
anticompl
activ
produc
ivig
intact
igg
princip
compon
led
manufactur
limit
pepsin
treatment
use
specif
enzym
plasmin
chemic
modifi
product
chemic
modifi
ivig
produc
structur
intact
low
anticompl
activ
contain
igg
fragment
treatment
immunoglobulin
enzym
chemic
modif
suppress
spontan
complement
activ
sever
unintend
consequ
treatment
also
reduc
import
antibodi
biolog
activ
requir
clinic
efficaci
exampl
complement
activ
antigenantibodi
complex
play
import
role
kill
encapsul
bacteria
leukocyt
antibodi
chemic
physic
alter
rapidli
remov
circulatori
system
reticuloendotheli
system
thu
antibodi
enzymedigest
chemic
modifi
ivig
shown
reduc
bacteri
opson
activ
shorten
circul
halfliv
commerci
ivig
produc
larg
pool
human
plasma
first
concentr
igg
cold
ethanol
fraction
although
igg
produc
cold
ethanol
fraction
rel
pure
contain
trace
amount
highli
activ
contamin
potenti
caus
advers
event
previous
attribut
aggreg
contamin
includ
prekallikrein
activ
initi
product
potent
vasodil
bradykinin
prekallikrein
activ
coagul
factor
complement
protein
immunoglobulin
contamin
plasmin
plasminogen
degrad
igg
form
split
product
reduc
antibodi
activ
isg
storag
desir
produc
ivig
contain
nativ
igg
antibodi
fulli
activ
led
develop
ivig
use
purif
anion
exchang
deae
chromatographi
first
purifi
ivig
contain
none
trace
contamin
associ
advers
event
antibodi
biolog
activ
bacteri
opson
viru
neutral
higher
treat
product
virtual
commerci
ivig
produc
anion
exchang
chromatographi
step
contain
rel
low
level
trace
contamin
histor
ivig
freezedri
obtain
prepar
would
stabl
year
mccue
cowork
report
adjust
ph
produc
clear
physic
stabl
igg
solut
clinic
studi
demonstr
patient
toler
igg
solut
formul
ph
significantli
lower
customari
rang
product
repres
major
advanc
ivig
product
formul
tabl
list
commerci
ivig
prepar
current
soon
avail
north
america
nine
product
licens
unit
state
seven
produc
cold
ethanol
fraction
follow
purif
use
ion
exchang
chromatographi
seven
product
formul
liquid
two
freezedri
produc
specif
viru
inactiv
remov
step
incorpor
manufactur
procedur
transmiss
homolog
serum
hepat
whole
blood
plasma
serum
great
concern
develop
human
plasma
protein
yellow
fever
vaccin
stabil
human
serum
produc
case
hepat
militari
personnel
pool
human
plasma
present
higher
risk
hepat
transmiss
whole
blood
increas
probabl
pool
plasma
would
contamin
one
donor
human
albumin
solut
also
respons
hepat
transmiss
heat
use
inactiv
virus
protein
destruct
temperatur
protein
sharpli
defin
differ
protein
presenc
substrat
enzym
heat
temperatur
degre
higher
absenc
substrat
gelli
cowork
report
hepat
transmiss
albumin
elimin
heat
hour
c
viru
inactiv
albumin
heat
treatment
possibl
discoveri
addit
stabil
increas
heat
resist
albumin
human
albumin
mani
bind
site
hydrophob
molecul
play
major
role
transport
fatti
acid
fill
site
stabil
acetyltryptophan
capryl
acid
allow
albumin
withstand
heat
hour
c
sinc
albumin
measur
biolog
activ
full
impact
heat
albumin
known
unfortun
plasma
protein
solut
inactiv
heat
earli
attempt
inactiv
virus
high
risk
plasma
product
unsuccess
high
risk
plasma
product
includ
fibrinogen
factor
viii
concentr
factor
ix
heat
albumin
solut
immunoglobulin
produc
cold
ethanol
fraction
consid
lowrisk
product
factor
viii
rapidli
inactiv
heat
solut
howev
dri
factor
viii
rel
heat
stabl
certain
condit
observ
led
develop
heattreat
factor
viii
prepar
fortun
hiv
also
inactiv
heat
factor
viii
product
lower
biolog
activ
rel
insolubl
produc
higher
incid
factor
viii
inhibitor
unfortun
nona
nonb
hepat
inactiv
percept
immunoglobulin
produc
cold
ethanol
fraction
low
risk
transmit
viru
infect
chang
lane
report
experiment
ivig
produc
cold
ethanol
fraction
transmit
nona
nonb
hepat
period
hiv
isol
shown
transmit
blood
blood
product
emerg
hiv
report
nona
nonb
hepat
transmiss
ivig
product
caus
manufactur
regulatori
agenc
examin
exist
ivig
manufactur
procedur
capac
elimin
virus
develop
dedic
viru
inactiv
procedur
ivig
product
also
initi
studi
ivig
manufactur
procedur
reveal
cold
ethanol
fraction
remov
virus
two
mechan
inactiv
partit
sever
laboratori
demonstr
hiv
inactiv
cold
ethanol
condit
use
ivig
product
howev
vesicular
stomat
viru
sindbi
viru
use
model
hepat
c
viru
hcv
formerli
known
nona
nonb
stabl
similar
condit
given
success
heat
treatment
produc
albumin
lowrisk
transmit
hepat
heat
treatment
ivig
evalu
one
ivig
stabil
weightweight
sorbitol
ph
heat
c
hour
sever
envelop
virus
one
nonenvelop
viru
studi
virus
complet
inactiv
except
hcv
substanti
chang
igg
physicochem
biolog
properti
report
horowitz
report
solventdeterg
process
origin
develop
inactiv
virus
factor
viii
concentr
effect
viru
inactiv
process
igg
solut
solventdeterg
viru
inactiv
rapidli
adopt
sever
ivig
manufactur
tabl
inactiv
hepat
c
bovin
viral
diarrhea
viru
bvdv
surrog
hcv
report
liquid
ivig
formul
ph
incub
day
pepsin
digest
ph
also
shown
inactiv
sever
envelop
virus
recent
incub
immunoglobulin
solut
capryl
acid
shown
effect
procedur
inactiv
envelop
virus
manufactur
long
known
clarif
filtrat
cold
ethanol
fraction
intermedi
presenc
filter
aid
effect
viru
remov
procedur
manufactur
valid
process
viru
remov
step
see
tabl
burnoufradosevich
colleagu
studi
immunoglobulin
solut
protein
concentr
mgml
ogradi
colleagu
demonstr
nm
filter
remov
log
mous
type
c
retroviru
sv
prv
wherea
polioviru
remov
nm
filter
similar
result
obtain
mgml
igg
solut
omar
kempf
studi
effect
nanofiltr
remov
small
nonenvelop
virus
virus
studi
bovin
enteroviru
bev
nm
bovin
parvoviru
bpv
nm
minut
viru
mice
mvm
nm
nanofiltr
perform
filter
nomin
pore
size
nm
despit
small
size
viru
effici
remov
mgml
igg
solut
author
demonstr
remov
virus
smaller
diamet
pore
size
nanofilt
due
antibodi
bound
virus
nanofiltr
adopt
sever
ivig
manufactur
see
tabl
concomit
develop
viru
inactiv
remov
procedur
scientist
also
recogn
import
elimin
infect
donor
develop
sensit
test
bloodborn
pathogen
although
peopl
ill
alway
exclud
donat
blood
plasma
donor
feel
sick
clinic
symptom
earli
stage
infect
time
window
period
blood
plasma
donat
may
transmit
infect
thu
develop
donor
screen
test
involv
test
new
pathogen
also
test
ever
increas
sensit
elimin
window
period
infect
rtler
review
bloodborn
pathogen
respect
relev
transfus
relev
pathogen
consid
human
pathogen
caus
chronic
progress
wast
lethal
diseas
infecti
agent
preval
transfus
popul
criteria
hepat
b
viru
hbv
hcv
human
immunodefici
virus
type
character
relev
parvoviru
cytomegaloviru
hepat
virus
hav
classifi
occasion
relev
sinc
review
publish
nonenvelop
virus
parvoviru
hav
becom
relev
sever
acut
respiratori
syndromecorona
viru
sarscov
west
nile
viru
wnv
emerg
thu
relev
pathogen
transfus
evolv
concept
given
earli
concern
hepat
transmiss
identif
hepat
virus
develop
sensit
donor
screen
test
becam
high
prioriti
sensit
test
hbv
develop
use
elimin
infect
donor
unfortun
hbv
test
elimin
transfusionrel
hepat
search
one
nona
nonb
hepat
virus
initi
aid
epidem
led
rapid
develop
screen
test
antibodi
human
immunodefici
viru
genom
nona
nonb
hepat
viru
isol
use
develop
donor
screen
test
hcv
today
plasma
screen
antibodi
syphili
hcv
hbv
hiv
antigen
extrem
sensit
test
hcv
hbv
parvoviru
nucleic
acid
recent
introduc
use
elimin
window
period
donat
risk
transmit
prion
diseas
creutztfedtjakob
diseas
cjd
variant
creutzfeldtjakob
diseas
vcjd
transfus
human
blood
blood
product
theoret
time
howev
incub
time
develop
cjd
diseas
long
difficult
quantifi
risk
enough
uncertainti
relationship
vcjd
bovin
spongiform
encephalopathi
bse
regulatori
agenc
take
step
reduc
risk
donor
spent
month
unit
kingdom
present
permit
donat
blood
plasma
unit
state
europ
recent
observ
bse
scrapi
transmit
sheep
sheep
transfus
may
support
donor
deferr
program
trejo
colleagu
studi
remov
hamster
scrapi
protein
prp
sc
two
step
ivig
product
western
blot
infect
test
demonstr
prp
sc
remov
two
filtrat
step
one
step
depth
filtrat
step
common
ivig
manufactur
procedur
similar
studi
perform
gregori
colleagu
proteinas
k
resist
prp
prp
re
determin
western
blot
analysi
wherea
infect
measur
hamster
author
observ
depth
filtrat
presenc
filter
aid
nanofiltr
remov
prp
re
reactiv
transmiss
spongiform
encephalopathi
tse
infect
unit
state
clinic
trial
subject
primari
immunodefici
becom
increasingli
standard
food
drug
administr
fda
recommend
studi
measur
rate
seriou
bacteri
infect
regular
infus
investig
ivig
month
avoid
season
bias
seriou
infect
defin
bacteremiasepsi
bacteri
mening
osteomyelitissept
arthriti
bacteri
pneumonia
viscer
abscess
diagnost
criteria
list
statist
analysi
demonstr
upper
onesid
confid
interv
frequenc
acut
seriou
bacteri
infect
less
one
per
subject
per
year
infusion
advers
event
defin
occur
hour
follow
infus
test
product
regardless
factor
may
impact
possibl
causal
associ
product
administr
target
safeti
endpoint
upper
onesid
confid
limit
less
pharmacokinet
pk
data
obtain
least
patient
analysi
includ
total
igg
sever
specif
antibodi
deriv
plasma
concentrationtim
curv
halflif
area
curv
auc
auc
volum
distribut
maximum
concentr
cmax
time
start
infus
cmax
tmax
elimin
rate
constant
serum
sampl
antibodi
measur
taken
washout
period
estim
halfliv
infus
investig
igiv
fda
also
desir
trough
igg
igg
subclass
level
measur
monthli
result
polici
illustr
tabl
time
period
record
infusion
tempor
associ
advers
event
extend
minut
hour
postinfus
studi
report
incid
acut
seriou
bacteri
infect
bacteri
infect
although
shown
tabl
pharmacokinet
studi
also
perform
product
number
pk
subject
rang
tabl
ivig
product
still
produc
cold
ethanol
fraction
purifi
anion
exchang
chromatographi
deae
anion
exchang
equival
plasma
fraction
cold
ethanol
fraction
involv
precipit
protein
adjust
ph
salt
concentr
temperatur
ethanol
concentr
precipit
protein
remov
protein
still
solut
intraven
immunoglobulin
filtrat
centrifug
abund
plasma
protein
igg
albumin
vastli
differ
physicochem
properti
readili
separ
howev
igg
albumin
distribut
fraction
precipit
step
classic
cohnoncley
process
fraction
ii
igg
purifi
least
three
addit
precipit
igg
loss
step
sinc
igg
product
drive
forc
behind
plasma
manufactur
capac
manufactur
turn
attent
increas
amount
purifi
igg
plasma
manufactur
limit
igg
precipit
plasma
singl
cold
ethanol
precipit
step
produc
cohn
refer
fraction
igg
loss
minim
use
fraction
ifibrinogen
precipit
earlier
start
materi
anion
exchang
chromatographi
viru
inactiv
remov
step
incorpor
process
import
increas
igg
yield
illustr
tabl
demand
ivig
increas
past
decad
manufactur
abl
meet
demand
acquir
underutil
facil
expand
exist
facil
build
new
facil
increas
yield
ivig
manufactur
chang
accompani
increas
clinic
trial
patient
primari
immunodefici
also
trend
formul
ivig
solut
protein
concentr
mgml
solut
low
ph
favor
product
stabil
ph
increas
igg
concentr
reduc
infus
time
import
featur
patient
primari
immunodefici
receiv
larg
dose
everi
day
life
ten
percent
ivig
low
ph
stabl
low
ionic
strength
therefor
sodium
chlorid
longer
ad
addit
carbohydr
stabil
longer
requir
tendenc
precipit
increas
ionic
strength
product
type
may
dilut
salin
mix
ivig
contain
sodium
chlorid
intraven
immunoglobulin
